SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, has announced that endocrinologist Dr. Glenn D. Braunstein is the company’s new Chief Medical Officer. Dr. Braunstein takes on the role after serving on Pathway Genomics’ Strategic Advisory Board. With a special interest in pharmacogenomics, Dr. Braunstein’s first priority will be Pathway Genomics’ pharmacogenomic testing menu.
Dr. Braunstein is the former Vice President of Clinical Innovation and Director of the Thyroid Cancer Program at the world-renowned Cedars-Sinai Medical Center. His distinguished career also includes 26 years as Chair of the Department of Medicine at Cedars-Sinai and Vice Chair of the Department of Medicine at the David Geffen School of Medicine at UCLA. At Cedars-Sinai he also held the James R. Klinenberg, M.D. Chair in Medicine and is currently Professor of Medicine there.
“Dr. Braunstein’s unparalleled experience and depth of knowledge make him an invaluable asset to Pathway Genomics during this period of tremendous growth,” said Jim Plante, Pathway Genomics’ founder and CEO. “His expertise will help us continue to develop the most cutting-edge genetic tests and deliver clinically actionable information to providers for their patients.”
Dr. Braunstein has made prominent advances in both reproductive endocrinology and thyroid cancer research and is an active editorial board member for several journals, including American Family Physician, American Journal of Medicine, and Reviews in Endocrinology and Metabolism. Dr. Braunstein also has more than 200 peer-reviewed publications, covering a range of endocrine issues as well as health care delivery models. He has served as chair and Special Advisor on committees at the Food and Drug Administration (FDA) and the American Board of Internal Medicine and was recently named “Top Endocrinologist” by the Los Angeles Business Journal.
Dr. Braunstein explains that “the era of personalized medicine has arrived,” referencing the Precision Medicine initiative introduced in President Obama’s recent State of the Union Address. He adds, “Healthcare providers can now use tailored genomic information to expand their diagnostic repertoire and enhance their patients’ knowledge of overall health and wellbeing. I believe Pathway Genomics is well positioned to help providers achieve not only better treatment outcomes, but also to use preventative strategies to help their patients avoid illness and medical complications.”
Dr. Braunstein earned both his bachelor’s and medical degree from the University of California, San Francisco, followed by an internship and residency at the Harvard University-affiliated Peter Bent Brigham Hospital (now part of Brigham and Women’s Hospital). Dr. Braunstein completed further training in endocrinology at the National Institutes of Health and Harbor General Hospital-UCLA School of Medicine.
About Pathway Genomics Corporation
Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation – making it a leader in the commercial healthcare industry. Focusing on providing users with the most validated and personalized healthcare information delivered to any device, the company’s program with IBM Watson is the first of its kind to merge artificial intelligence and deep learning with precision medicine, applicable to both consumers and providers.
Based in San Diego, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve, or maintain, health and wellness. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.